Health Care·Biotechnology·$3.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.66 | N/A | -17.86% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.66 | N/A | -17.86% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current market conditions impacting performance. They highlighted a commitment to long-term strategies without providing specific guidance.
Management acknowledged the challenges faced in the quarter.
They emphasized a focus on long-term growth despite current setbacks.
There were no specific plans shared for future performance improvements.
Twist Bioscience's earnings report indicates ongoing challenges, particularly reflected in the EPS miss. The stock fell 8.44% in response, suggesting investor disappointment. The lack of revenue figures and guidance adds uncertainty about the company's near-term outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
EATON CORP PLC
May 2, 2025